Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2022-09-02 Capital/Financing Update
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) and relates to the offering and sale of common stock by Aprea Therapeutics, Inc. It references a sales agreement and amendments to a previously filed prospectus. The content focuses on securities offering details, sales agreements, legal matters related to the offering, and risk factors. This type of document is a capital raising and financing update, not a financial report, earnings release, or regulatory filing about company operations or governance. It is not an announcement of a report but the actual offering document. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence classification.
2022-09-02 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 15, 2022, by Aprea Therapeutics, Inc. It reports a notification from Nasdaq regarding the company's failure to meet the continued listing requirement due to stockholders' equity deficiency. The document discusses the company's plan to regain compliance or transfer to another Nasdaq market. This is a regulatory announcement about a delisting risk and compliance plan, not a full financial report or earnings release. The key phrase 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' and the content about Nasdaq listing compliance clearly indicate this is a Delisting Announcement. The document length (5612 characters) and content confirm it is the actual announcement, not just a brief notice or report publication announcement.
2022-08-19 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2022, by Aprea Therapeutics, Inc. It announces the issuance of a press release with financial results for the second quarter ended June 30, 2022. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is furnished, not filed, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 4060 characters, which is relatively short and consistent with a Form 8-K announcement. The content corresponds to an Earnings Release announcement rather than the full earnings report or detailed financial statements. Therefore, the appropriate classification is Earnings Release (ER).
2022-08-11 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 28, 2022, by Aprea Therapeutics, Inc. It reports the submission of matters to a vote of security holders at the 2022 annual meeting. The content includes detailed voting results on various proposals such as director elections, stock issuance approval, reverse stock split proposal, equity incentive plan amendment, and auditor ratification. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings. The document is not an annual report, earnings release, or proxy statement, but specifically reports voting outcomes. The length and detail confirm it is not a brief announcement or a certification. Therefore, the correct classification is DVA with high confidence.
2022-08-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-08-01 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.